EYPT
EyePoint, Inc.
Price Chart
Latest Quote
$13.85
+0.27 (+1.99%)
Current Price
| Previous Close | $13.58 |
| Open | $13.62 |
| Day High | $14.01 |
| Day Low | $13.49 |
| Volume | 429,591 |
Stock Information
| Shares Outstanding | 83.84M |
| Total Debt | $17.62M |
| Cash Equivalents | $45.26M |
| Revenue | $7.61M |
| Net Income | $-271.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.16B |
| EPS (TTM) | $-3.51 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.26B |
| Sales | $7.61M |
| Income | $-271.60M |
| Book/sh | $0.40 |
| Cash/sh | $0.54 |
| Employees | 214 |
Financial Ratios
| Quick Ratio | 5.97 |
| Current Ratio | 6.66 |
| Debt/Eq | 46.82 |
Returns & Margins
| ROA | -54.13% |
| ROE | -102.71% |
| Operating Margin | -450.65% |
Ownership
| Insider Ownership | 3.68% |
| Institutional Ownership | 111.82% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.91 |
| P/S | 152.51 |
| P/B | 34.97 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $37.00 |
Technical Indicators
| SMA20 | $12.76 |
| SMA50 | $13.27 |
| SMA200 | $14.11 |
| RSI | 55.83 |
| ATR | 0.7643 |
| Shares Float | 70.47M |
| Short Float | 18.98% |
| Short Ratio | 16.43 |
| Volatility | 1.75 |
| Rel Volume | 0.38 |
Performance History
| Week | +6.29% |
| Month | +10.80% |
| Quarter | +4.69% |
| 6 Months | -16.87% |
| YTD | -20.77% |
| Year | +55.27% |
| 3 Years | +97.01% |
| 5 Years | +42.49% |
| 10 Years | -52.89% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $13.85 | 429,867 |
| 2026-06-18 | $13.58 | 1,290,300 |
| 2026-06-17 | $13.15 | 1,180,500 |
| 2026-06-16 | $12.88 | 1,471,600 |
| 2026-06-15 | $12.08 | 1,083,900 |
| 2026-06-12 | $13.03 | 1,091,400 |
| 2026-06-11 | $12.50 | 1,260,300 |
| 2026-06-10 | $12.33 | 1,161,500 |
| 2026-06-09 | $11.77 | 1,874,100 |
| 2026-06-08 | $11.45 | 805,700 |
| 2026-06-05 | $11.78 | 925,200 |
| 2026-06-04 | $12.26 | 815,100 |
| 2026-06-03 | $12.34 | 837,700 |
| 2026-06-02 | $12.53 | 993,500 |
| 2026-06-01 | $13.15 | 1,308,100 |
| 2026-05-29 | $13.58 | 1,060,500 |
| 2026-05-28 | $13.50 | 1,435,500 |
| 2026-05-27 | $13.16 | 1,826,000 |
| 2026-05-26 | $13.35 | 918,100 |
| 2026-05-22 | $12.93 | 783,800 |
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
đ° Latest News
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
MarketBeat âĸ 2026-05-26T16:04:15Z
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets
Simply Wall St. âĸ 2026-05-21T05:13:28Z
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Motley Fool âĸ 2026-05-17T18:33:40Z
Erasca Stock Is Up 715%. Hereâs Why One Biotech Fund Still Bought $68 Million More
Motley Fool âĸ 2026-05-17T18:18:17Z
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness
Simply Wall St. âĸ 2026-05-17T13:14:56Z
EyePoint (EYPT) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-07T15:51:41Z
EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T12:30:00Z
Eyepoint Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T15:54:16Z
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-06T12:25:03Z
Is It Time To Reassess EyePoint (EYPT) After A 120% One Year Share Price Surge
Simply Wall St. âĸ 2026-05-06T12:15:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,066,000 | $3,712,000 | $4,632,000 | $7,930,000 |
| Cost Of Revenue | $2,066,000 | $3,712,000 | $4,632,000 | $8,326,000 |
| Total Revenue | $31,371,000 | $43,273,000 | $46,018,000 | $41,404,000 |
| Operating Revenue | $31,371,000 | $43,273,000 | $46,018,000 | $41,404,000 |
| Expenses | ||||
| Interest Expense | $33,000 | $14,000 | $1,247,000 | $3,189,000 |
| Total Expenses | $274,805,000 | $189,127,000 | $121,085,000 | $120,342,000 |
| Net Non Operating Interest Income Expense | $11,751,000 | $15,074,000 | $5,702,000 | $-1,058,000 |
| Interest Expense Non Operating | $33,000 | $14,000 | $1,247,000 | $3,189,000 |
| Operating Expense | $272,739,000 | $185,415,000 | $116,453,000 | $112,016,000 |
| Selling And Marketing Expense | $90,000 | $131,000 | $11,689,000 | $25,507,000 |
| General And Administrative Expense | $51,610,000 | $52,358,000 | $40,102,000 | $34,817,000 |
| Other Income Expense | - | - | $-1,347,000 | $-22,258,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-231,962,000 | $-130,870,000 | $-70,795,000 | $-102,254,000 |
| Net Interest Income | $11,751,000 | $15,074,000 | $5,702,000 | $-1,058,000 |
| Interest Income | $11,784,000 | $15,088,000 | $6,949,000 | $2,131,000 |
| Normalized Income | $-231,962,000 | $-130,870,000 | $-69,730,870 | $-79,996,000 |
| Net Income From Continuing And Discontinued Operation | $-231,962,000 | $-130,870,000 | $-70,795,000 | $-102,254,000 |
| Total Operating Income As Reported | $-243,434,000 | $-145,854,000 | $-75,067,000 | $-99,637,000 |
| Net Income Common Stockholders | $-231,962,000 | $-130,870,000 | $-70,795,000 | $-102,254,000 |
| Net Income | $-231,962,000 | $-130,870,000 | $-70,795,000 | $-102,254,000 |
| Net Income Including Noncontrolling Interests | $-231,962,000 | $-130,870,000 | $-70,795,000 | $-102,254,000 |
| Net Income Continuous Operations | $-231,962,000 | $-130,870,000 | $-70,795,000 | $-102,254,000 |
| Pretax Income | $-231,683,000 | $-130,780,000 | $-70,712,000 | $-102,254,000 |
| Special Income Charges | $0 | $0 | $-1,347,000 | $-22,258,000 |
| Interest Income Non Operating | $11,784,000 | $15,088,000 | $6,949,000 | $2,131,000 |
| Operating Income | $-243,434,000 | $-145,854,000 | $-75,067,000 | $-78,938,000 |
| Gross Profit | $29,305,000 | $39,561,000 | $41,386,000 | $33,078,000 |
| Depreciation Amortization Depletion Income Statement | - | - | $0 | $2,050,000 |
| Depreciation And Amortization In Income Statement | - | - | $0 | $2,050,000 |
| Amortization Of Intangibles Income Statement | - | - | $0 | $2,050,000 |
| Per Share | ||||
| Diluted EPS | $-3.17 | $-2.32 | $-1.82 | $-2.74 |
| Basic EPS | $-3.17 | $-2.32 | $-1.82 | $-2.74 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-282,870 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-229,341,000 | $-129,226,000 | $-67,654,000 | $-74,361,000 |
| Total Unusual Items | $0 | $0 | $-1,347,000 | $-22,258,000 |
| Total Unusual Items Excluding Goodwill | $0 | $0 | $-1,347,000 | $-22,258,000 |
| Reconciled Depreciation | $2,309,000 | $1,540,000 | $464,000 | $2,446,000 |
| EBITDA (Bullshit earnings) | $-229,341,000 | $-129,226,000 | $-69,001,000 | $-96,619,000 |
| EBIT | $-231,650,000 | $-130,766,000 | $-69,465,000 | $-99,065,000 |
| Diluted Average Shares | $73,251,000 | $56,298,000 | $38,904,000 | $37,317,000 |
| Basic Average Shares | $73,251,000 | $56,298,000 | $38,904,000 | $37,317,000 |
| Diluted NI Availto Com Stockholders | $-231,962,000 | $-130,870,000 | $-70,795,000 | $-102,254,000 |
| Tax Provision | $279,000 | $90,000 | $83,000 | $0 |
| Research And Development | $221,039,000 | $132,926,000 | $64,662,000 | $49,642,000 |
| Selling General And Administration | $51,700,000 | $52,489,000 | $51,791,000 | $60,324,000 |
| Other Gand A | $51,610,000 | $52,358,000 | $40,102,000 | $34,817,000 |
| Other Special Charges | - | - | $1,347,000 | $1,559,000 |
| Impairment Of Capital Assets | - | - | $0 | $20,699,000 |
| Amortization | - | - | $0 | $2,050,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $306,113,000 | $336,501,000 | $266,323,000 | $96,368,000 |
| Total Assets | $363,996,000 | $418,465,000 | $355,184,000 | $180,356,000 |
| Total Non Current Assets | $35,341,000 | $35,159,000 | $10,384,000 | $7,548,000 |
| Other Non Current Assets | $6,095,000 | $5,982,000 | $150,000 | $150,000 |
| Current Assets | $328,655,000 | $383,306,000 | $344,800,000 | $172,808,000 |
| Other Current Assets | $1,964,000 | $1,405,000 | $1,009,000 | $782,000 |
| Prepaid Assets | $18,141,000 | $8,076,000 | $8,030,000 | $9,076,000 |
| Inventory | $1,813,000 | $2,305,000 | $3,906,000 | $2,886,000 |
| Receivables | $651,000 | $607,000 | $805,000 | $15,503,000 |
| Accounts Receivable | $651,000 | $607,000 | $805,000 | $15,503,000 |
| Cash Cash Equivalents And Short Term Investments | $306,086,000 | $370,913,000 | $331,050,000 | $144,561,000 |
| Cash And Cash Equivalents | $101,821,000 | $99,704,000 | $281,263,000 | $95,633,000 |
| Goodwill And Other Intangible Assets | - | - | - | $0 |
| Other Intangible Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $20,772,000 | $21,858,000 | $4,906,000 | $45,769,000 |
| Long Term Debt And Capital Lease Obligation | $20,772,000 | $21,858,000 | $4,906,000 | $35,294,000 |
| Long Term Debt | - | - | - | $29,310,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $10,475,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $57,883,000 | $81,964,000 | $88,861,000 | $83,988,000 |
| Total Non Current Liabilities Net Minority Interest | $20,859,000 | $32,916,000 | $25,598,000 | $49,451,000 |
| Other Non Current Liabilities | $87,000 | $205,000 | - | $600,000 |
| Non Current Deferred Liabilities | $0 | $10,853,000 | $20,692,000 | $13,557,000 |
| Current Liabilities | $37,024,000 | $49,048,000 | $63,263,000 | $34,537,000 |
| Other Current Liabilities | $2,140,000 | $1,440,000 | $646,000 | $579,000 |
| Current Deferred Liabilities | $0 | $17,784,000 | $38,592,000 | $1,205,000 |
| Payables And Accrued Expenses | $20,350,000 | $17,994,000 | $11,394,000 | $12,763,000 |
| Payables | $10,490,000 | $11,721,000 | $6,504,000 | $5,919,000 |
| Accounts Payable | $10,490,000 | $11,721,000 | $6,504,000 | $5,919,000 |
| Equity | ||||
| Common Stock Equity | $306,113,000 | $336,501,000 | $266,323,000 | $96,368,000 |
| Total Equity Gross Minority Interest | $306,113,000 | $336,501,000 | $266,323,000 | $96,368,000 |
| Stockholders Equity | $306,113,000 | $336,501,000 | $266,323,000 | $96,368,000 |
| Gains Losses Not Affecting Retained Earnings | $961,000 | $1,028,000 | $864,000 | $786,000 |
| Other Equity Adjustments | $961,000 | $1,028,000 | $864,000 | $786,000 |
| Retained Earnings | $-1,104,978,000 | $-873,016,000 | $-742,146,000 | $-671,351,000 |
| Other | ||||
| Ordinary Shares Number | $82,826,416 | $68,266,005 | $49,043,074 | $34,082,934 |
| Share Issued | $82,826,416 | $68,266,005 | $49,043,074 | $34,082,934 |
| Tangible Book Value | $306,113,000 | $336,501,000 | $266,323,000 | $96,368,000 |
| Invested Capital | $306,113,000 | $336,501,000 | $266,323,000 | $136,153,000 |
| Working Capital | $291,631,000 | $334,258,000 | $281,537,000 | $138,271,000 |
| Capital Lease Obligations | $20,772,000 | $21,858,000 | $4,906,000 | $5,984,000 |
| Total Capitalization | $306,113,000 | $336,501,000 | $266,323,000 | $125,678,000 |
| Additional Paid In Capital | $1,410,047,000 | $1,208,421,000 | $1,007,556,000 | $766,899,000 |
| Capital Stock | $83,000 | $68,000 | $49,000 | $34,000 |
| Common Stock | $83,000 | $68,000 | $49,000 | $34,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $10,853,000 | $20,692,000 | $13,557,000 |
| Long Term Capital Lease Obligation | $20,772,000 | $21,858,000 | $4,906,000 | $5,984,000 |
| Current Deferred Revenue | $0 | $17,784,000 | $38,592,000 | $1,205,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,534,000 | $11,830,000 | $12,631,000 | $9,515,000 |
| Current Accrued Expenses | $9,860,000 | $6,273,000 | $4,890,000 | $6,844,000 |
| Net PPE | $29,246,000 | $29,177,000 | $10,234,000 | $7,398,000 |
| Accumulated Depreciation | $-6,017,000 | $-4,057,000 | $-2,571,000 | $-2,107,000 |
| Gross PPE | $35,263,000 | $33,234,000 | $12,805,000 | $9,505,000 |
| Leases | $4,180,000 | $4,128,000 | $1,008,000 | $1,008,000 |
| Construction In Progress | $1,460,000 | $1,507,000 | $3,728,000 | $0 |
| Other Properties | $29,623,000 | $27,599,000 | $8,069,000 | $8,497,000 |
| Properties | $0 | $0 | $0 | $0 |
| Work In Process | $584,000 | $648,000 | $882,000 | $1,078,000 |
| Raw Materials | $1,229,000 | $1,657,000 | $1,303,000 | $1,410,000 |
| Other Short Term Investments | $204,265,000 | $271,209,000 | $49,787,000 | $48,928,000 |
| Finished Goods | - | $0 | $1,721,000 | $398,000 |
| Line Of Credit | - | - | $0 | $10,475,000 |
| Current Capital Lease Obligation | - | - | - | $579,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-243,390,000 | $-130,278,000 | $-1,608,000 | $-67,155,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-240,110,000 | $-126,226,000 | $1,875,000 | $-65,005,000 |
| Cash Flow From Continuing Operating Activities | $-240,110,000 | $-126,226,000 | $1,875,000 | $-65,005,000 |
| Operating Gains Losses | - | - | $1,347,000 | $1,559,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,280,000 | $-4,052,000 | $-3,483,000 | $-2,150,000 |
| Investing Cash Flow | $68,580,000 | $-219,355,000 | $-3,315,000 | $-17,265,000 |
| Cash Flow From Continuing Investing Activities | $68,580,000 | $-219,355,000 | $-3,315,000 | $-17,265,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $173,445,000 | $163,314,000 | $226,174,000 | $0 |
| Financing Cash Flow | $173,647,000 | $164,022,000 | $187,070,000 | $-690,000 |
| Cash Flow From Continuing Financing Activities | $173,647,000 | $164,022,000 | $187,070,000 | $-690,000 |
| Net Other Financing Charges | $-1,931,000 | $-5,184,000 | $-1,970,000 | $-3,188,000 |
| Net Common Stock Issuance | $173,445,000 | $163,314,000 | $226,174,000 | $0 |
| Common Stock Issuance | $173,445,000 | $163,314,000 | $226,174,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-105,000 | $-105,000 | $-45,811,000 | $-71,772,000 |
| End Cash Position | $101,971,000 | $99,854,000 | $281,413,000 | $95,783,000 |
| Beginning Cash Position | $99,854,000 | $281,413,000 | $95,783,000 | $178,743,000 |
| Changes In Cash | $2,117,000 | $-181,559,000 | $185,630,000 | $-82,960,000 |
| Proceeds From Stock Option Exercised | $2,238,000 | $5,997,000 | $3,377,000 | $395,000 |
| Net Issuance Payments Of Debt | $-105,000 | $-105,000 | $-40,511,000 | $2,103,000 |
| Net Long Term Debt Issuance | $-105,000 | $-105,000 | $-40,511,000 | $2,103,000 |
| Long Term Debt Payments | $-105,000 | $-105,000 | $-45,811,000 | $-71,772,000 |
| Net Investment Purchase And Sale | $71,705,000 | $-215,303,000 | $168,000 | $-15,115,000 |
| Sale Of Investment | $323,725,000 | $183,000,000 | $55,284,000 | $124,000,000 |
| Purchase Of Investment | $-252,020,000 | $-398,303,000 | $-55,116,000 | $-139,115,000 |
| Net PPE Purchase And Sale | $-3,125,000 | $-4,052,000 | $-3,483,000 | $-2,150,000 |
| Sale Of PPE | $155,000 | $0 | - | - |
| Purchase Of PPE | $-3,280,000 | $-4,052,000 | $-3,483,000 | $-2,150,000 |
| Change In Working Capital | $-33,781,000 | $-27,773,000 | $58,882,000 | $-3,023,000 |
| Change In Other Working Capital | $-28,137,000 | $-29,028,000 | $44,484,000 | $-799,000 |
| Change In Other Current Liabilities | $-33,000 | $0 | - | - |
| Change In Other Current Assets | $-113,000 | $-5,832,000 | $0 | - |
| Change In Payables And Accrued Expense | $4,677,000 | $5,731,000 | $1,519,000 | $1,198,000 |
| Change In Inventory | $492,000 | $1,600,000 | $-1,553,000 | $-760,000 |
| Change In Receivables | $-10,667,000 | $-244,000 | $14,432,000 | $-2,662,000 |
| Changes In Account Receivables | $-10,667,000 | $-244,000 | $14,432,000 | $-2,662,000 |
| Other Non Cash Items | $-4,828,000 | $-5,953,000 | $-856,000 | $-558,000 |
| Stock Based Compensation | $27,873,000 | $36,740,000 | $12,057,000 | $14,177,000 |
| Deferred Tax | $279,000 | $90,000 | $83,000 | $0 |
| Deferred Income Tax | $279,000 | $90,000 | $83,000 | $0 |
| Depreciation Amortization Depletion | $2,309,000 | $1,540,000 | $464,000 | $2,446,000 |
| Depreciation And Amortization | $2,309,000 | $1,540,000 | $464,000 | $2,446,000 |
| Depreciation | $2,309,000 | $1,540,000 | $464,000 | $396,000 |
| Net Income From Continuing Operations | $-231,962,000 | $-130,870,000 | $-70,795,000 | $-102,254,000 |
| Issuance Of Debt | - | $0 | $5,300,000 | $73,875,000 |
| Interest Paid Supplemental Data | - | $0 | $1,405,000 | $2,600,000 |
| Long Term Debt Issuance | - | $0 | $5,300,000 | $73,875,000 |
| Provisionand Write Offof Assets | - | $0 | $693,000 | $1,949,000 |
| Net Short Term Debt Issuance | - | - | $-10,475,000 | $10,475,000 |
| Short Term Debt Payments | - | - | $-15,775,000 | $-33,400,000 |
| Short Term Debt Issuance | - | - | $5,300,000 | $43,875,000 |
| Asset Impairment Charge | - | - | $0 | $20,699,000 |
| Amortization Cash Flow | - | - | $0 | $2,050,000 |
| Amortization Of Intangibles | - | - | $0 | $2,050,000 |
| Income Tax Paid Supplemental Data | - | - | - | $600,000 |
| Effect Of Exchange Rate Changes | - | - | - | - |
Fetched: 2026-06-16